These results clearly showthat the development of BiTEs for PCa therapy is a viable approach,and data presented in this report extend the findings in the literature.Here, we use our recently developed 5D3 antibody with high specificityand nanomolar affinity toward PSMA37−39 to engineer 5D3 BiTEderivatives that effectively mediate T-cell cytotoxicity toward PSMA-expressingcells in sub-nanomolar concentrations. The gene discussed is FOLH1; the disease is posterior cortical atrophy.